SELF-ASSESSMENT FORM

QIs		TARGETS (tick if applicable)		Scoring points			
General indicators							
1.	Number of newly diagnosed endometrial carcinoma cases treated per centre per year	Optimal target: ≥90		8*			
		Minimum required target: ≥ 50		5**			
2.	Number of endometrial carcinoma primary surgeries (including early and advanced stages)	Optimal target: ≥80		8*			
	performed per centre per year	Minimum required target: ≥ 50		5**			
3.	Surgery performed by a gynecologic oncologist or a trained surgeon specifically dedicated to gynaecological cancer management (primary and relapsed cases)	≥95%		5*			
4.	Treatment and/or follow-up plan discussed at a multi-disciplinary team meeting (all FIGO stages and ESGO risk groups)	Primary treatment: 90%		3: both targets are met			
	stages and ESGO risk groups)	Relapse treatment: 99%		0: all other situations			
5.	Centre participating in ongoing prospective studies in gynaecological oncology	Optimal target: participation in ongoing prospective studies in endometrial carcinoma		5*			
		Minimum required target: participation in ongoing prospective studies in gynaecological oncology		3			
Preop	erative work-up						
6.	Proportion of patients with a preoperative work-up according to the ESGO-ESTRO-ESP guidelines (primary setting)	90%		3			
7.	Proportion of presumed FIGO stage I-II upstaged to IVB disease	<5%		4			
Compl	liance of the intraoperative management with the standards of care						
8.	Proportion of all presumed early stage endometrial carcinoma cases with non ruptured uterus after hysterectomy	99%		8			
9.	Proportion of patients with all presumed early stage endometrial carcinoma who underwent	Optimal target: ≥80%		7			
	successful minimally invasive surgery	Minimum required target: 60%		4			
10.	Proportion of patients with BMI > 35 kg/m² who underwent successful minimally invasive surgery	>60%		5*			
11.	Proportion of conversions from minimally invasive surgery to open surgery (primary setting)	<10%		3			
12.	Proportion of patients with intraoperative injuries (primary and relapsed setting)	<2%		5			
13.	Proportion of infracolic omentectomy in endometrial carcinoma patients with presumed early stage serous, undifferentiated carcinoma or carcinosarcoma	≥90%		2			
14.	Proportion of lymph node staging performed in patients with presumed early stage high- intermediate or high-risk endometrial carcinoma	>85%		5			
15.	Proportion of sentinel lymph node procedures in patients with presumed early stage, undergoing lymph node staging	90%		7*			
16.	Number of sentinel lymph node procedures for endometrial carcinoma performed or supervised per surgeon per year	≥20		5			
17.	Proportion of indocyanine green cervical injection	≥95%		2*			
18.	Proportion of high-intermediate/high-risk patients with side-specific systematic pelvic lymphadenectomy in case of failed sentinel lymph node detection	>90%		4			
19.	Proportion of patients who underwent ultrastaging of sentinel lymph nodes	≥99%		7			
20.	Proportion of bilateral mapping rate of sentinel lymph node procedures	≥75%		5*			
21.	Proportion of complete macroscopic resection for curative intent in patients with primary advanced endometrial carcinoma (stage III-IV)	≥75%		6*			
22.	Proportion of patients who underwent salvage surgery for locoregional recurrent disease (isolated pelvic or nodal recurrent disease) in whom complete macroscopic resection is achieved	≥85%		5*			
* Mandatory to be a centre of excellence ⇔Optimal target should be met (if any) ** Mandatory for accreditation ⇔ Minimum required target should be met							

QIs (continued)		TARGETS (tick if applicable)		Scoring points			
Molec							
23.	Proportion of patients undergoing complete molecular classification of their tumour according to the ESGO-ESTRO-ESP guidelines	Optimal target: ≥90% Minimum required target: ≥50%		5* 3			
24.	Compliance with the ESGO-ESTRO-ESP adjuvant treatment guidelines	≥90%		6			
Recor	ding pertinent information to improve quality of care						
25.	Minimum required elements in surgical reports (primary and relapsed setting)	≥99%		3			
26.	Minimum required elements in pathology reports (primary and relapsed setting)	≥99%		2			
27.	Structured morbidity and mortality conference per year for quality assurance of surgical care	Optimal target: 4		5			
		Minimum required target: 2		3			
28.	Proportion of reoperations within 30 days for complications after primary minimally invasive surgery	≤2%		5			
29.	Structured prospective reporting of recurrences/deaths	≥ once a year		5			
◆ ADDITIONAL REQUIREMENT (CENTRE OF EXCELLENCE) ◆							
	Publication of 3 articles on endometrial carcinoma authored by a gynaecological surgical oncology member of the team over the last 3 years, including at least one article as first or last author			_*			
⇒ PLEASE INDICATE THE SUM OF YOUR INDIVIDUAL SCORES /143**←							

 $^{* \} Mandatory \ to \ be \ a \ centre \ of \ excellence$

Entry criteria for standard ESGO certification for endometrial carcinoma surgery

- ⇒ Sum of the individual scores ≥ 115 (>80% of the score)
- All the following criteria must apply (minimum required targets should be met): 1, 2

Requirements for ESGO certification for endometrial carcinoma surgery as a Centre of Excellence

- ⇒ Sum of the individual scores ≥ 115 (> 80% of the score)
- \Rightarrow All the following criteria must apply (optimal targets should be met (if any)): 1, 2, 3, 5, 10, 15, 17, 20, 21, 22, 29
- Publication of 3 articles on endometrial carcinoma authored by a gynaecological surgical oncology member of the team over the last 3 years, including at least one article as first or last author

 $^{** \}textit{Maximum score if all optimal targets are met}.$